Dapagliflozin alleviates renal inflammation and protects against diabetic kidney diseases, both dependent and independent of blood glucose levels
IntroductionDiabetic kidney disease (DKD) has become the leading cause of end-stage renal disease worldwide. Therefore, efforts to understand DKD pathophysiology and prevent its development at the early phase are highly warranted.MethodsHere, we analyzed kidneys from healthy mice, diabetic mice, and...
Main Authors: | Anxiang Cai, Jianxiao Shen, Xiaoqian Yang, Xinghua Shao, Leyi Gu, Shan Mou, Xiajing Che |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-11-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1205834/full |
Similar Items
-
Dapagliflozin Restores Impaired Autophagy and Suppresses Inflammation in High Glucose-Treated HK-2 Cells
by: Jing Xu, et al.
Published: (2021-06-01) -
Nephroprotective effect of dapagliflozin in type 2 diabetes mellitus: A potential role of Klotho protein
by: I. Topchii, et al.
Published: (2021-06-01) -
Changes in glycemic control and skeletal muscle mass indices after dapagliflozin treatment in individuals with type 1 diabetes mellitus
by: Yuta Yoshimura, et al.
Published: (2023-10-01) -
Comparative Pharmacokinetics and Pharmacodynamics of a Novel Sodium-Glucose Cotransporter 2 Inhibitor, DWP16001, with Dapagliflozin and Ipragliflozin
by: Min-Koo Choi, et al.
Published: (2020-03-01) -
DAPA-HF trial: dapagliflozin evolves from a glucose-lowering agent to a therapy for heart failure
by: Edgardo Kaplinsky
Published: (2020-02-01)